Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000
Debt
Debt-to-Equity Ratio0.24
Current Ratio2.92
Quick Ratio2.62
Price-To-Earnings
Trailing P/E Ratio-114.38
Forward P/E Ratio-61.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$903.37 million
Price / Sales7.11
Cash Flow$0.2685 per share
Price / Cash153.94
Book Value$7.82 per share
Price / Book5.29
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-157,940,000.00
Net Margins-13.81%
Return on Equity-0.29%
Return on Assets-0.19%
Miscellaneous
Employees2,000
Outstanding Shares155,320,000
Market Cap$6.59 billion
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) announced its quarterly earnings results on Thursday, July, 26th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.40. The business had revenue of $304.64 million for the quarter, compared to analyst estimates of $261.58 million. Alkermes had a negative net margin of 13.81% and a negative return on equity of 0.29%. The company's revenue was up 39.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
How can I listen to Alkermes' earnings call?
Alkermes will be holding an earnings conference call on Tuesday, October 23rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8884248151.
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share (EPS) guidance of ($0.06)-$0.12 for the period, compared to the Thomson Reuters consensus estimate of $0.02. The company issued revenue guidance of $975 million-$1.025 billion, compared to the consensus revenue estimate of $1.00 billion.
What price target have analysts set for ALKS?
13 analysts have issued 1-year price targets for Alkermes' stock. Their forecasts range from $42.00 to $81.00. On average, they expect Alkermes' stock price to reach $56.00 in the next year. This suggests a possible upside of 35.5% from the stock's current price. View Analyst Price Targets for Alkermes.
What is the consensus analysts' recommendation for Alkermes?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada continue to drive growth for the company. The company also reiterated its guidance. primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being the phase III data readout for ALKS 3831 in schizophrenia, submission of BIIB098 (ALKS 8700) NDA and phase I data read-out for ALKS 4230. Regulatory review is underway for ALKS 5461 being evaluated for major depressive disorder. In July 2018, FDA approved a label expansion of Aristada- Aristada Initio which in combination with a single 30 milligram dose of oral aripiprazole, is designed to enable initiation of Aristada on day one and replaces the need for 21 days of oral supplementation. However, Alkermes is highly dependent on manufacturing and/or royalty revenue. Share price of Alkermes have outperformed industry in past one month. Earnings estimates have increased ahead of Q3 earnings release." (10/10/2018)
- 2. Cantor Fitzgerald analysts commented, "FDA response looks like someone may not have been listening. The nature of the FDA response to ALKS stands in stark contrast to a comment by the CEO on the 2Q17 results conference call, Earlier this week, we passed a major milestone with the outcome of our pre-NDA meeting with the FDA, which resulted in an agreement on our NDA submission content and timing." We generally take with a grain of salt any management comments that FDA meetings went well" or were productive" but we believe investors may have been led to believe that the FDA viewed the ALKS 5461 data as potentially adequate for approval. That the FDA evidently has asked for additional clinical studies strongly calls into question such an assumption, in our opinion." (4/2/2018)
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Teva Pharmaceutical Industries (TEVA), Mylan (MYL), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Bausch Health Companies (BHC) and Alnylam Pharmaceuticals (ALNY).
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 56)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 81)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 51)
- Mr. James A. Robinson Jr., Pres & COO (Age 48)
- Mr. Iain Michael Brown, Sr. VP of Fin. & Chief Accounting Officer (Age 49)
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (0.36%), Rhenman & Partners Asset Management AB (0.19%), Bank of Montreal Can (0.01%), Andra AP fonden (0.01%), Nisa Investment Advisors LLC (0.01%) and Clarus Wealth Advisors (0.00%). Company insiders that own Alkermes stock include David Joseph Gaffin, Elliot Ehrich, Floyd E Bloom, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which major investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including Andra AP fonden and Nisa Investment Advisors LLC. Company insiders that have sold Alkermes company stock in the last year include Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops and Shane Cooke. View Insider Buying and Selling for Alkermes.
Which major investors are buying Alkermes stock?
ALKS stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., Rhenman & Partners Asset Management AB, Clarus Wealth Advisors and Bank of Montreal Can. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $41.33.
How big of a company is Alkermes?
Alkermes has a market capitalization of $6.59 billion and generates $903.37 million in revenue each year. The company earns $-157,940,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Alkermes employs 2,000 workers across the globe.
What is Alkermes' official website?
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (NASDAQ ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
